[1]
|
Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., Stein, K.D., Alteri, R. and Jemal, A. (2016) Cancer Treatment and Survivorship Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 271-289.
https://doi.org/10.3322/caac.21349
|
[2]
|
Guo, S., Chen, W., Luo, Y., Ren, F., Zhong, T., Rong, M., Dang, Y., Feng, Z. and Chen, G. (2015) Clinical Implication of Long Non-Coding RNA NEAT1 Expression in Hepatocellular Carcinoma Patients. International Journal of Clinical and Experimental Pathology, 8, 5395-5402.
|
[3]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.
https://doi.org/10.3322/caac.21332
|
[4]
|
Waghray, A., Murali, A.R. and Menon, K.N. (2015) Hepatocellular Carci-noma: From Diagnosis to Treatment. World Journal of Hepatology, 7, 1020-1029. https://doi.org/10.4254/wjh.v7.i8.1020
|
[5]
|
Uygun Ilikhan, S., Bilici, M., Sahin, H., Demir Akca, A.S., Can, M., Oz, I.I., Guven, B., Buyukuysal, M.C. and Ustundag, Y. (2015) Assessment of the Correlation between Serum Prolidase and Alpha Fetoprotein Levels Inpatients with Hepatocellular Carcinoma. World Journal of Gastroenterology, 21, 6999-7007.
https://doi.org/10.3748/wjg.v21.i22.6999
|
[6]
|
Waghray, A., Murali, A.R. and Menon, K.N. (2015) Hepatocellular Carcinoma: From Diagnosis to Treatment. World Journal of Hepatology, 7, 1020-1029. https://doi.org/10.4254/wjh.v7.i8.1020
|
[7]
|
Kamath, P.S., Wiesner, R.H., Malinchoc, M., Kremers, W., Therneau, T.M., Kosberg, C.L., D’Amico, G., Dickson, E.R. and Kim, W.R. (2001) A Model to Predict Survival in Patients with End-Stage Liver Disease. Hepatology, 33, 464-470. https://doi.org/10.1053/jhep.2001.22172
|
[8]
|
Virchow, R.L.K. (1863) Die krankhaften Geschwülste. August Hirschwald, Berlin.
|
[9]
|
Hanahan, D. and Weinberg, R.A. (2011) Hall-marks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[10]
|
Kladney, R.D., Bulla, G.A., Guo, L., et al. (2000) GP73, a Novel Golgi-Localized Protein Upregulated by Viral Infection. Gene, 249, 53-65. https://doi.org/10.1016/S0378-1119(00)00136-0
|
[11]
|
Kladney, R.D., Cui, X., Bulla, G.A., Brunt, E.M. and Fim-mel, C.J. (2002) Expression of GP73, a Resident Golgi Membrane Protein, in Viral and Nonviral Liver Disease. Hepa-tology, 35, 1431-1440.
https://doi.org/10.1053/jhep.2002.32525
|
[12]
|
毛一雷, 杨华瑜, 徐海峰, 桑新亭, 卢欣, 杨志英, 张锦春, 钟守先, 黄洁夫, 张宏冰. 新的肝癌血清标记物GP73在肝癌诊断中的初步研究[J]. 中华医学杂志, 2008(14): 948-951.
|
[13]
|
Ali, O.M., et al. (2020) Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagno-sis of Hepatocellular Carcinoma. International Journal of General Medicine, 13, 193-200. https://doi.org/10.2147/IJGM.S253622
|
[14]
|
Shaker, M.K., et al. (2020) Evaluation of Golgi Protein 73 (GP73) as a Potential Biomarkers for Hepatocellular Carcinoma. Clinical Laboratory, 66. https://doi.org/10.7754/Clin.Lab.2020.190911
|
[15]
|
Xiao, J., et al. (2019) Development and Potential Application of a Simultaneous Multiplex Assay of Golgi Protein 73 and Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis. European Review for Medical and Pharmacological Sciences, 23, 3302-3310.
|
[16]
|
Fang, Y.-S., et al. (2021) Do Com-bined Assays of Serum AFP, AFP-L3, DCP, GP73, and DKK-1 Efficiently Improve the Clinical Values of Biomarkers in Decision-Making for Hepatocellular Carcinoma? A Meta-Analysis. Expert Review of Gastroenterology & Hepatology, 15, 1065-1076. https://doi.org/10.1080/17474124.2021.1900731
|
[17]
|
赵运胜, 王春华, 高芹, 廖飞, 张丽娜, 崔辰莹. GP73、AFP-L3、GPC-3和DCP联合检测在低浓度AFP小肝癌诊断中的价值及验证[J]. 检验医学与临床, 2017, 14(1): 19-23.
|
[18]
|
Pepys, M.B. and Hirschfield, G.M. (2003) C-Reactive Protein: A Critical Update. Journal of Clinical Investigation, 111, 1805-1812. https://doi.org/10.1172/JCI200318921
|
[19]
|
Pierce, B.L., Ballard-Barbash, R., Bernstein, L., Baumgartner, R.N., Neuhouser, M.L., Wener, M.H., et al. (2009) Elevated Biomarkers of Inflammation Are Associated with Reduced Survival among Breast Cancer Patients. Journal of Clinical Oncology, 27, 3437-3444. https://doi.org/10.1200/JCO.2008.18.9068
|
[20]
|
Fukuchi, M., Kuwabara, K., Tsuji, Y., Baba, H., Ishibashi, K., Chika, N., et al. (2013) C-Reactive Protein Is a Negative Independent Factor in Patients with Stage IV Colorectal Cancer Undergoing Oxaliplatin-Based Chemotherapy. Anticancer Research, 33, 5051-5055.
|
[21]
|
Jin, Y., Sun, Y., Shi, X., Zhao, J., Shi, L. and Yu, X. (2014) Prognostic Value of Circulating C-Reactive Protein Levels in Patients with Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis. Journal of Cancer Research and Therapeutics, 10, C160-C166. https://doi.org/10.4103/0973-1482.145854
|
[22]
|
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E. and Heik-enwalder, M. (2018) The Immunology of Hepatocellular Carcinoma. Nature Immunology, 19, 222-232. https://doi.org/10.1038/s41590-018-0044-z
|
[23]
|
Sieghart, W., Pinter, M., Hucke, F., Graziadei, I., Schöniger-Hekele, M., Müller, C., et al. (2013) Single Determination of C-Reactive Protein at the Time of Diagnosis Predicts Long-Term Outcome of Patients with Hepatocellular Carcinoma. Hepatology, 57, 2224-2234. https://doi.org/10.1002/hep.26057
|
[24]
|
Meischl, T., Rasoul-Rockenschaub, S., Györi, G., Sieghart, W., Reiberger, T., Trauner, M., Soliman, T., Berlakovich, G. and Pinter, M. (2019) C-Reactive Protein Is an Independent Predictor for Hepatocellular Carcinoma Recurrence after Liver Transplantation. PLOS ONE, 14, e0216677. https://doi.org/10.1371/journal.pone.0216677
|
[25]
|
Zhang, Y., Lu, L., He, Z., Xu, Z., Xiang, Z., Nie, R.C., Lin, W., Chen, W., Zhou, J., Yin, Y., Xie, J., Zhang, Y., Zheng, X., Zhu, T., Cai, X., Li, P., Chao, X. and Cai, M.Y. (2022) C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. Frontiers in Im-munology, 13, Article ID: 808101.
https://doi.org/10.3389/fimmu.2022.808101
|
[26]
|
Carr, B.I., Ince, V., Bag, H.G., Usta, S., Ersan, V., Isik, B. and Yilmaz, S. (2021) CRP Is a Superior and Prognostically Significant Inflammation Biomarker for Hepatocellular Cancer Patients Treated by Liver Transplantation. Clinics and Practice, (London), 18, 1626-1632.
|
[27]
|
Hussain, S.P. and Harris, C.C. (2007) Inflammation and Cancer: An Ancient Link with Novel Potentials. International Journal of Cancer, 121, 2373-2380. https://doi.org/10.1002/ijc.23173
|
[28]
|
Chew, V., Tow, C., Teo, M., Wong, H.L., Chan, J., Gehring, A., et al. (2010) Inflammatory Tumour Microenvironment Is Associated with Superior Survival in Hepatocellular Carcinoma Patients. Journal of Hepatology, 52, 370-379.
https://doi.org/10.1016/j.jhep.2009.07.013
|
[29]
|
Qin, L.X. (2012) Inflammatory Immune Responses in Tumor Mi-croenvironment and Metastasis of Hepatocellular Carcinoma. Cancer Microenvironment, 5, 203-209. https://doi.org/10.1007/s12307-012-0111-1
|
[30]
|
Salvagno, G.L., Sanchis-Gomar, F., Picanza, A., et al. (2015) Red Blood Cell Distribution Width: A Simple Parameter with Multiple Clinical Applications. Critical Reviews in Clinical La-boratory Sciences, 52, 86-105.
https://doi.org/10.3109/10408363.2014.992064
|
[31]
|
Nemeth, E. and Ganz, T. (2014) Anemia of Inflammation. Hematology/Oncology Clinics of North America, 28, 671-681. https://doi.org/10.1016/j.hoc.2014.04.005
|
[32]
|
Smirne, C., Grossi, G., Pinato, D.J., et al. (2015) Evaluation of the Red Cell Distribution width as a Biomarker of Early Mortality in Hepatocellular Carcinoma. Digestive and Liver Disease, 47, 488-494.
https://doi.org/10.1016/j.dld.2015.03.011
|
[33]
|
Wei, T.-T., et al. (2016) Elevated Red Blood Cell Distribution Width Is Associated with Liver Function Tests in Patients with Primary Hepatocellular Carcinoma. Clinical Hemorheology and Microcirculation, 64, 149-155.
https://doi.org/10.3233/CH-162053
|
[34]
|
Lan, F., et al. (2017) Increased Red Cell Distribution Width Is Strong In-flammatory Marker of Liver Diseases in a Guangxi Population. Clinical Laboratory, 63, 389-398. https://doi.org/10.7754/Clin.Lab.2016.160626
|
[35]
|
Jing, J.-S., et al. (2020) Red Cell Distribution Width as a Prognostic Factor in Patients with Hepatocellular Carcinoma. Clinical Laboratory, 66. https://doi.org/10.7754/Clin.Lab.2019.191027
|
[36]
|
Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
|
[37]
|
Kim, J. and Bae, J.S. (2016) Tumor-Associated Macro-phages and Neutrophils in Tumor Microenvironment. Mediators of Inflammation, 2016, Article ID: 6058147. https://doi.org/10.1155/2016/6058147
|
[38]
|
Dan, J., Zhang, Y., Peng, Z., Huang, J., Gao, H., Xu, L., et al. (2013) Postoperative Neutrophil-to-Lymphocyte Ratio Change Predicts Survival of Patients with Small Hepatocellular Carcino-ma Undergoing Radiofrequency Ablation. PLOS ONE, 8, e58184. https://doi.org/10.1371/journal.pone.0058184
|
[39]
|
Mano, Y., Shirabe, K., Yamashita, Y., Harimoto, N., Tsujita, E., Takeishi, K., et al. (2013) Preoperative Neutrophil-to-Lymphocyte Ratio Is a Predictor of Survival after Hepatectomy for Hepatocellular Carcinoma: A Retrospective Analysis. Annals of Surgery, 258, 301-305. https://doi.org/10.1097/SLA.0b013e318297ad6b
|
[40]
|
McNally, M.E., Martinez, A., Khabiri, H., Guy, G., Michaels, A.J., Hanje, J., et al. (2013) Inflammatory Markers Are Associated with Outcome in Patients with Unresec-table Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Surgical Oncology, 20, 923-928. https://doi.org/10.1245/s10434-012-2639-1
|
[41]
|
Qi, X., Li, J., Deng, H., Li, H., Su, C. and Guo, X. (2016) Neu-trophil-to-Lymphocyte Ratio for the Prognostic Assessment of Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis Of Observational Studies. Oncotarget, 7, 45283-45301. https://doi.org/10.18632/oncotarget.9942
|
[42]
|
Sellers, C.M., Uhlig, J., Ludwig, J.M., Stein, S.M. and Kim, H.S. (2019) Inflammatory Markers in Intrahepatic Cholangiocarcinoma: Effects of Advanced Liver Disease. Cancer Medicine, 8, 5916-5929.
https://doi.org/10.1002/cam4.2373
|
[43]
|
Hong, Y.M., Yoon, K.T., Hwang, T.H., Heo, J., Woo, H.Y. and Cho, M. (2019) Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. European Journal of Gastroenterology & Hepatology, 31, 1250-1255. https://doi.org/10.1097/MEG.0000000000001405
|
[44]
|
Wang, Y., Peng, C., Cheng, Z., Wang, X., Wu, L., Li, J., et al. (2018) The Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Hepatectomy: A Systemic Review and Meta-Analysis. International Journal of Surgery, 55, 73-80. https://doi.org/10.1016/j.ijsu.2018.05.022
|
[45]
|
Wong, L., Bozhilov, K., Hernandez, B., Kwee, S., Chan, O., Ellis, L. and LeMarchand, L. (2019) Underlying Liver Disease and Advanced Stage Liver Cancer Are Associated with Elevated Neutrophil-Lymphocyte Ratio. Clinical and Molecular Hepatology, 25, 305-316. https://doi.org/10.3350/cmh.2019.0004
|
[46]
|
Roxburgh, C.S. and McMillan, D.C. (2010) Role of Systemic In-flammatory Response in Predicting Survival in Patients with Primary Operable Cancer. Future Oncology, 6, 149-163. https://doi.org/10.2217/fon.09.136
|
[47]
|
Wang, D.S., Luo, H.Y., Qiu, M.Z., et al. (2012) Comparison of the Prog-nostic Values of Various Inflammation Based Factors in Patients with Pancreatic Cancer. Medical Oncology, 29, 3092-3100.
https://doi.org/10.1007/s12032-012-0226-8
|
[48]
|
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Immunobi-ology of Cancer Immunosurveillance and Immunoediting. Immunity, 21, 137-148. https://doi.org/10.1016/j.immuni.2004.07.017
|
[49]
|
Suner, A., Carr, B., Akkiz, H., Uskudar, O., Kuran, S., Tokat, Y., et al. (2019) Inflammatorymarkers C-Reactive Protein and PLR in Relation to HCC Characteristics. Journal of Translational Science, 5, 1-6.
https://doi.org/10.15761/JTS.1000260
|
[50]
|
Wu, W., Wang, Q., Han, D., Li, J., Nie, Y., Guo, D., Yang, L., Tao, K., Zhang, X. and Dou, K. (2021) Prognostic Value of Preoperative Inflammatory Markers in Patients with Hepatocellular Carcinoma Who Underwent Curative Resection. Cancer Cell International, 21, 500. https://doi.org/10.1186/s12935-021-02204-3
|
[51]
|
Dertli, R., Asil, M., Biyik, M., Karakarcayildiz, A., Keskin, M., Göktepe, H.M., Kayar, Y. and Ataseven, H. (2021) Can Hematological Inflammatory Parameters Predict Mortality in Hepatocellular Carcinoma? Journal of Gastrointestinal Cancer, 52, 666-675. https://doi.org/10.1007/s12029-020-00448-2
|
[52]
|
张婷婷, 王湘漪, 郭紫薇, 丁小胜, 梁军. 血小板与淋巴细胞比值对肝细胞癌患者预后影响的Meta分析[J]. 肿瘤防治研究, 2018, 45(10): 775-780.
|
[53]
|
Asher, V., Lee, J., In-namaa, A., et al. (2011) Preoperative Platelet Lymphocyte Ratio as an Independent Prognostic Marker in Ovarian Cancer]. Clinical and Translational Oncology, 13, 499-503.
https://doi.org/10.1007/s12094-011-0687-9
|
[54]
|
Azab, B., Shah, N., Radbel, J., et al. (2013) Pretreatment Neutro-phil/Lymphocyte Ratio Is Superior to Platelet/Lymphocyte Ratio as a Predictor of Long-Term Mortality in Breast Cancer Patients. Medical Oncology, 30, 432.
https://doi.org/10.1007/s12032-012-0432-4
|
[55]
|
Wang, D., Wu, M., Feng, F.Z., et al. (2012) Pretreatment Neu-trophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Do Not Predict Survival in Patients with Cervical Cancer Treated with Neoadjuvant Chemotherapy and Radical Hysterectomy. Chinese Medical Journal, 126, 1464-1468.
|